EMEA-001864-PIP01-15-M07

Table of contents

Key facts

Invented name
Takhzyro
Active substance
Lanadelumab (DX-2930)
Therapeutic area
Other
Decision number
P/0214/2022
PIP number
EMEA-001864-PIP01-15-M07
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Prevention of hereditary angioedema attacks
Route(s) of administration
Subcutaneous use
Contact for public enquiries
Takeda Pharmaceuticals International AG Ireland Branch

E-mail: medinfoemea@takeda.com
Tel: +44 (0) 3333 000181

Decision type
PM: decision on the application for modification of an agreed PIP
Compliance procedure number
EMEA-C-001864-PIP01-15-M07
Compliance opinion date
09/09/2022
Compliance outcome
positive

Decision

Related content

How useful was this page?

Add your rating